The list includes 49 medications for chronic conditions and 51 for acute care, with an aim of informing efforts to improve supply chain reliability, according to a March 4 news release from the nonprofit organization.
The analysis, based on data from sources including the USP Medicine Supply Map, found that 71% of the drugs identified as the most vulnerable are injectables, including sodium chloride injection, dextrose injection, heparin sodium injection, propofol and lidocaine hydrochloride injection.
The report also highlights that while 61% of the medicines listed were not in shortage as of January 2025, they remain at high risk of shortage.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
